Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma.
The clinical behavior of renal cell carcinoma (RCC) cannot be predicted by histological and other markers. In this study, comparative genomic hybridization was used to evaluate whether the number of genomic aberrations has prognostic significance in 41 nonmetastatic clear cell RCC extending beyond the renal capsule. Losses were most prevalent at 3p (56%) and 9p and 13q (24% each). The number of DNA losses per tumor was associated with recurrence-free survival (P = 0.03). DNA gains most often involved chromosome 5q (17%) and chromosome 7 (15%). The number of DNA gains was not associated with clinical outcome. Loss of chromosome 9p was the only individual locus associated with recurrence (P = 0.04), suggesting that a tumor suppressor gene on chromosome 9p may play a role in RCC progression.
Moch
H
H
Department of Laboratory Medicine, University of California San Francisco 94143-0808, USA.
Presti
J C
JC
Sauter
G
G
Buchholz
N
N
Jordan
P
P
Mihatsch
M J
MJ
Waldman
F M
FM
D002292:Carcinoma, Renal Cell / Q000235:genetics* / Q000503:physiopathology; D002869:Chromosome Aberrations; D006801:Humans; D007680:Kidney Neoplasms / Q000235:genetics* / Q000503:physiopathology; D009693:Nucleic Acid Hybridization; D011237:Predictive Value of Tests; D011379:Prognosis